Rebecca A. English – författare
Visar alla böcker från författaren Rebecca A. English. Handla med fri frakt och snabb leverans.
16 produkter
Transforming Clinical Research in the United States
Challenges and Opportunities: Workshop Summary
Av and Translation Forum on Drug Discovery, Development, Board on Health Sciences Policy m. fl.
E-bok, 2010
500 kr
Lägg i varukorg
An ideal health care system relies on efficiently generating timely, accurate evidence to deliver on its promise of diminishing the divide between clinical practice and research. There are growing indications, however, that the current health care system and the clinical research that guides …
Building a National Framework for the Establishment of Regulatory Science for Drug Development
Workshop Summary
Av and Translation Forum on Drug Discovery, Development, Board on Health Sciences Policy m. fl.
E-bok, 2011
295 kr
Lägg i varukorg
The Food and Drug Administration (FDA) is tasked with ensuring the safety and effectiveness of medicine. FDA''s science base must be strong enough to make certain that regulatory decisions are based on the best scientific evidence. The IOM held a public workshop on February 26, 2010, to examine the …
Transforming Clinical Research in the United States
Challenges and Opportunities: Workshop Summary
Av and Translation Forum on Drug Discovery, Development, Board on Health Sciences Policy m. fl.
E-bok, 2010
714 kr
Lägg i varukorg
An ideal health care system relies on efficiently generating timely, accurate evidence to deliver on its promise of diminishing the divide between clinical practice and research. There are growing indications, however, that the current health care system and the clinical research that guides …
Building a National Framework for the Establishment of Regulatory Science for Drug Development
Workshop Summary
Av and Translation Forum on Drug Discovery, Development, Board on Health Sciences Policy m. fl.
E-bok, 2011
428 kr
Lägg i varukorg
The Food and Drug Administration (FDA) is tasked with ensuring the safety and effectiveness of medicine. FDA''s science base must be strong enough to make certain that regulatory decisions are based on the best scientific evidence. The IOM held a public workshop on February 26, 2010, to examine the …
Public Engagement and Clinical Trials
New Models and Disruptive Technologies: Workshop Summary
Av and Translation Forum on Drug Discovery, Development, Board on Health Sciences Policy m. fl.
E-bok, 2012
576 kr
Lägg i varukorg
Clinical trials provide essential information needed to turn basic medical research findings into patient treatments. New treatments must be studied in large numbers of humans to find out whether they are effective and to assess any harm that may arise from treatment. There is growing recognition …
Facing the Reality of Drug-Resistant Tuberculosis in India
Challenges and Potential Solutions: Summary of a Joint Workshop by the Institute of Medicine, the Indian National Science Academy, and the Indian Council of Medical Research
Av and Translation Forum on Drug Discovery, Development, Board on Health Sciences Policy m. fl.
E-bok, 2012
749 kr
Lägg i varukorg
An estimated 8.8 million people fell ill with tuberculosis (TB) in 2010 and 1.4 million died from the disease. Although antibiotics to treat TB were developed in the 1950s and are effective against a majority of TB cases, resistance to these antibiotics has emerged over the years, resulting in the …
Envisioning a Transformed Clinical Trials Enterprise in the United States
Establishing an Agenda for 2020: Workshop Summary
Av and Translation Forum on Drug Discovery, Development, Board on Health Sciences Policy m. fl.
E-bok, 2012
714 kr
Lägg i varukorg
There is growing recognition that the United States'' clinical trials enterprise (CTE) faces great challenges. There is a gap between what is desired - where medical care is provided solely based on high quality evidence - and the reality - where there is limited capacity to generate timely and …
Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis
Workshop Summary
Av Institute of Medicine, Board on Health Sciences Policy m. fl.
Häftad, 2013
722 kr
Lägg i varukorg
To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with …
Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis
Workshop Summary
Av and Translation Forum on Drug Discovery, Development, Board on Health Sciences Policy m. fl.
E-bok, 2013
642 kr
Lägg i varukorg
To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with …
Realizing the Promise of Equity in the Organ Transplantation System
Av and Distribution Committee on A Fairer and More Equitable, Cost-Effective, and Transparent System of Donor Organ Procurement, Allocation, Kenneth W. Kizer m. fl.
E-bok, 2022
874 kr
Lägg i varukorg
Each year, the individuals and organizations in the U.S. organ donation, procurement, allocation, and distribution system work together to provide transplants to many thousands of people, but thousands more die before getting a transplant due to the ongoing shortage of deceased donor organs and …
Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS
Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences
Av Institute of Medicine, Board on Health Sciences Policy m. fl.
Häftad, 2014
460 kr
Lägg i varukorg
Multidrug-resistant tuberculosis (TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally developed and introduced in the 1950 and 1960s. Since 2008, the Forum on Drug Discovery, Development, and Translation of the Institute of …
Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS
Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences
Av and Translation Forum on Drug Discovery, Development, Board on Health Sciences Policy m. fl.
E-bok, 2014
696 kr
Lägg i varukorg
Multidrug-resistant tuberculosis (TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally developed and introduced in the 1950 and 1960s. Since 2008, the Forum on Drug Discovery, Development, and Translation of the Institute of …
Large Simple Trials and Knowledge Generation in a Learning Health System
Workshop Summary
Av Roundtable on Value and Science-Driven Health Care, and Translation Forum on Drug Discovery, Development m. fl.
E-bok, 2013
553 kr
Lägg i varukorg
Randomized clinical trials (RCTs) are often referred to as the "gold standard" of clinical research. However, in its current state, the U.S. clinical trials enterprise faces substantial challenges to the efficient and effective conduct of research. Streamlined approaches to RCTs, such as large …
Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products
Workshop Summary
Av and Translation Forum on Drug Discovery, Development, Board on Health Sciences Policy m. fl.
E-bok, 2014
678 kr
Lägg i varukorg
Despite the extensive body of evidence that informs regulatory decisions on pharmaceutical products, significant uncertainties persist, including the underlying variability in human biology, factors associated with the chemistry of a drug, and limitations in the research and clinical trial process …
Physician-Assisted Death
Scanning the Landscape: Proceedings of a Workshop
Av Board on Health Sciences Policy, Health and Medicine Division m. fl.
E-bok, 2018
803 kr
Lägg i varukorg
The question of whether and under what circumstances terminally ill patients should be able to access life-ending medications with the aid of a physician is receiving increasing attention as a matter of public opinion and of public policy. Ethicists, clinicians, patients, and their families debate …
Living with ALS
Av Committee on Amyotrophic Lateral Sclerosis: Accelerating Treatments and Improving Quality of Life, Board on Health Care Services m. fl.
E-bok, 2024
349 kr
Lägg i varukorg
At any one time, at least 30,000 people in the U.S. are living with amyotrophic lateral sclerosis (ALS), a rapidly progressive, fatal neurological disease affecting individuals, caregivers, at-risk genetic carriers, and others. In 2022, Congress directed the National Institutes of Health to …
